Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Virbac Earnings Release 2009

Jan 19, 2010

1753_iss_2010-01-19_85b1c203-e650-48e7-956b-5d457c55294a.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Annual sales grow by 5.4% in 2009

Consolidated numbers
- provisional -
in million Euros
2009 2008 % change Evolution
at constant
exchange
rates
Evolution
at constant
scope and
rates
1st quarter 109.0 103.2 +5.6% +7.3% +3.3%
nd quarter
2
116.5 108.6 +7.2% +5.9% +3.0%
1st half-year 225.5 211.8 +6.4% +6.6% +3.1%
3rd quarter 122.2 114.8 +6.4% +6.9% +8.0%
4th quarter 119.4 116.7 +2.3% +2.9% +3.1%
nd half-year
2
241.6 231.5 +4.4% +4.9% +5.5%
Total year net sales 467.1 443.4 +5.4% +5.7% +4.4%

Sales continued to grow in the fourth quarter at a good pace, albeit significantly slowed down by the persisting weakness of the food producing animals market in France.

On an annual basis, the sales growth is very close to the previously released estimates with a 5.7% evolution at constant exchange rates and 4.4% at constant scope. All regions have contributed to this performance, in particular the US with the good growth of the product ranges brought to the veterinary channel; Europe with the contribution of new products ; emerging countries which continued growing. Almost all of the major Group products performed positively.

Sales in the companion animals segment have increased by 7.5% at constant exchange rates, benefiting from the launch of new products in Europe, notably Easotic – a product for ear treatment – and Effipro – an external parasiticide based on Fipronil –, as well as the penetration of Iverhart in the US. In the food producing animals segment the sales growth has reached 6% at constant exchange rates and 1.7% at constant scope : the portfolio of products acquired from Schering Plough in Europe last year performed in line with objectives and the positive trend in emerging markets (India, South Africa, Mexico, Brazil, …) have compensated for the difficult situation faced on the French market in this area.

VIRBAC : Passionate about Animal Health NYSE Euronext – Compartment B / ISIN : FR0000031577 / MNEMO : VIRP Corporate Finance : tél. 33 4 92 08 71 32 E-mail : [email protected] – Website : www.virbac.com